The Biomedical Research Institute of Málaga and Nanomedicine Platform (IBIMA) is participating in the groundbreaking European project BRECISE, which aims to revolutionize the diagnosis and treatment of prostate and bladder cancer through advanced biomarkers and Artificial Intelligence technologies. This ambitious initiative is funded by the Horizon Europe program and the Innovative Health Initiative (IHI).
The Biomedical Research Institute of Málaga and Nanomedicine Platform has joined an ambitious European project designed to transform cancer care. The BRECISE project (Biomarker-Driven Research for Enhanced Cancer Innovation and Standardized Evaluation), funded under the Horizon Europe program with co-funding from the Innovative Health Initiative (IHI) and the private sector, is now making its way to Spain.
BRECISE seeks to accelerate the clinical validation and implementation of Next-Generation Sequencing (NGS)-based biomarkers and Artificial Intelligence (AI) models to enhance cancer diagnosis, treatment selection, and disease monitoring in prostate and bladder cancer. This innovative approach will integrate clinical and molecular data to develop personalized treatments that improve diagnostic precision and patient outcomes.
What are the project’s objectives?
-
Multicenter studies to validate biomarkers for risk stratification, treatment response, and disease progression.
-
Development of AI-based models to enhance diagnostic accuracy and predictive capacity.
-
Use of micro-tumor and organoid models to evaluate drug responses in real-time before treatment initiation.
-
Compliance with European regulations, including the European Health Data Space, the Artificial Intelligence Act, and the Medical Devices Regulation.
What is the expected impact?
The BRECISE project is set to make a significant impact on patients and European healthcare systems:
-
For patients: More precise and early diagnoses, reduced unnecessary treatments, and early detection of therapy resistance.
-
For healthcare systems: Optimized treatment allocation, reduced costs associated with ineffective therapies, and a standardized biomarker validation process.
-
For industry and policymakers: Regulatory alignment with European healthcare frameworks and strengthening Europe’s leadership in precision oncology.
International Collaboration
Led by Philips Research and the South East Technological University, the BRECISE consortium brings together 30 partners, including academic institutions, research centers, healthcare providers, industry leaders, and patient organizations. IBIMA is proud to be part of this multidisciplinary collaboration, ensuring that scientific advancements translate into tangible clinical impact.
Tags BRECISE • cancer • IHI • Lucha contra el cáncer